Skip to main content
Smart Investors Daily
AK

NASDAQ · AKTS

Aktis Oncology, Inc.

Healthcare · Biotechnology

$16.16

Down-$0.46 (-2.77%)

Updated Nov 17, 2026, 5:24 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.06B
P/E ratio
0
Dividend yield
0.00%
52-week range
$0.03 – $34.19
Volume
597.52K
Avg. volume
374.39K

Price performance · AKTS

AKTS price history

1M range · 0 trading sessions · Daily adjusted prices

AKTS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AKTS news

The latest Smart Investors Daily articles mentioning AKTS.

AKTS research

Overview

Company profile and research snapshot.

Company profile

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.92
Implied upside
—
Analysts
—
AKTS recent ratings
DateFirmRatingTarget
Oct 2, 2026WedbushOutperform—
Sep 9, 2026OppenheimerOutperform—
Aug 19, 2026WedbushOutperform—
Aug 19, 2026BMO CapitalOutperform—
Jul 14, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Aktis: Q3 Earnings Snapshot

BOSTON (AP) — BOSTON (AP) — Aktis Oncology Inc. (AKTS) on Thursday reported a loss of $29.

Yahoo · Nov 12, 2026

Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress

Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumorsStarted first backfill cohorts in the ongoing Phase 1b NECTINIUM-2 clinical trial of AKY-1189 and Phase 1b BActinium-1 clinical trial of AKY-2519On track to present preliminary data for AKY-1189 in first quarter of 2027 and AKY-2519 in 2027 BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”),

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.